Market Cap
$274.6M
AMRN
AMARIN CORP PLC\UK
$12.55 ▼ -1.38%
Prev close $12.72Market cap$274.6M
12-mo target$12.50 (-0.4%)
High Impact Filing (7/10)3 New Institutional Positions Biotech & Drug Discovery
Snapshot
The big-picture read on AMRN right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Inst. Holders
44 funds
Inst. Value
$17.3M
Inst. Activity
3 buys / 2 sells
SEC Reports
3
Press Releases
2
Price chart 30d -8.4%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 15, 2026 short_interest_report
Aug 28, 2026 Press Short Interest: AMRN up 3% to 0.5M shares
Settlement 2026-09-15 | Days to cover: 10.10 | ≈2.49% of shares outstanding (est.)
Amarin announced a post-hoc analysis from the REDUCE-IT trial at ESC 2026, showing that highly adherent patients on icos
Impact 4/10
Aug 1, 2026 Insider
Fishman Peter L. acquired via exercise 313 shares
SVP, CFO
Aug 1, 2026 Insider
Fishman Peter L. surrendered for taxes 155 shares
SVP, CFO @ $14.26 ($2.2K)
Aug 1, 2026 Insider
Fishman Peter L. was granted 313 shares
SVP, CFO
Jun 30, 2026 Inst.
MILLENNIUM MANAGEMENT LLC — TRIM
115,808 shares ($1.8M)
Jun 30, 2026 Inst.
Jun 4, 2026 SEC RENAISSANCE TECHNOLOGIES LLC — DOUBLED
48,369 shares ($771.0K)
The Supreme Court unanimously reversed the Federal Circuit, holding that Amarin failed to state a claim for induced infr
COURT-RULING — Impact 7/10
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Jun 25, 2025 | Goldman Sachs | MAINTAIN | Sell | 54% |
| Apr 17, 2025 | Goldman Sachs | MAINTAIN | Sell | 54% |
| Jun 20, 2024 | Cantor Fitzgerald | REITERATE | Overweight | 49% |
| Jun 18, 2024 | Cantor Fitzgerald | REITERATE | Overweight | 49% |
| Oct 25, 2023 | Jefferies | DOWNGRADE | Hold | 53% |
| Jul 20, 2023 | Goldman Sachs | MAINTAIN | Sell | 54% |
| Jul 19, 2023 | Northland Capital Markets | MAINTAIN | Market Perform | 51% |
| Jan 6, 2023 | Jefferies | UPGRADE | Buy | 53% |
| Oct 19, 2022 | SVB Leerink | MAINTAIN | Market Perform | — |
| May 24, 2022 | Goldman Sachs | MAINTAIN | Sell | 54% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 0 | 0 | 2 | 3 | 2 | 0% | |
| Aug 1, 2026 | 0 | 0 | 2 | 2 | 2 | 0% | |
| Jul 1, 2026 | 0 | 0 | 3 | 2 | 2 | 0% | |
| Jun 1, 2026 | 0 | 0 | 3 | 2 | 2 | 0% | |
| May 1, 2026 | 0 | 0 | 3 | 2 | 2 | 0% | |
| Apr 1, 2026 | 0 | 0 | 3 | 2 | 2 | 0% | |
| Mar 1, 2026 | 0 | 0 | 3 | 2 | 2 | 0% | |
| Feb 1, 2026 | 0 | 0 | 3 | 2 | 2 | 0% |
Price targets
Where 2 covering analysts think AMRN trades over the next 12 months.
$12.50 -0.4% upside Hold
Current$12.55 Low$12.00 Median$12.50 High$13.00 2 analysts
$12.00$13.00
Analyst rating None as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
3 SEC filing reports analyzed · 0 bullish, 2 bearish, 0 mixed, 1 neutral · avg impact 5.7/10.Plus 2 press releases.
BEARISHCOURT-RULING7/10
The Supreme Court unanimously reversed the Federal Circuit, holding that Amarin failed to state a cl
Jun 4, 2026
NEUTRAL8-K4/10
Amarin reported Q1 2026 revenue of $45.1M (+7% YoY), beating the $43.8M consensus, but GAAP EPS was
Apr 29, 2026
BEARISH8-K6/10
Amarin reported Q4 2025 financial results showing a 21% year-over-year decline in total net revenue
Feb 25, 2026
NEUTRAL4/10
Amarin announced a post-hoc analysis from the REDUCE-IT trial at ESC 2026, showing that highly adher
Aug 28, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 15, 2026
short_interest_report
Short Interest: AMRN up 3% to 0.5M shares
Settlement 2026-09-15 | Days to cover: 10.10 | ≈2.49% of shares outstanding (est.)
Aug 31, 2026
other
Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026
Presentations Expand Understanding of Treatment Adherence, Long-Term Outcomes, Lipoprotein(a), Coagulation Biomarkers, and Potential Mechanisms of Eic
Aug 28, 2026
fda
New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients
Data Supports Approximately 30% Relative Risk Reduction Among Highly Adherent Patients and Provides Evidence Consistent with a Potential Legacy Effect
Aug 24, 2026
fda
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026
DUBLIN and BRIDGEWATER, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of
Jul 29, 2026
earnings
Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence
Q2 2026 Results Highlight Global Volume Growth, Lower Operating Expenses and Positive Cash Flow
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.02 | $-0.02–$-0.02 | 95.0% | — | 0↑ 1↓ | $0.0B | 1 |
| Next Q | $-0.01 | $-0.01–$-0.01 | 0.0% | — | — | $0.0B | 1 |
| Current FY | $-0.07 | $-0.07–$-0.07 | 22.2% | -133.3% | 0↑ 1↓ | $0.2B | 1 |
| Next FY | $-0.06 | $-0.06–$-0.06 | 14.3% | -200.0% | 0↑ 1↓ | $0.2B | 1 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.020 | — |
| 7d ago | $-0.020 | — |
| 30d ago | $0.000 | -0.020 |
| 60d ago | $-0.005 | -0.015 |
| 90d ago | $-0.005 | -0.015 |
Institutional ownership
Which big funds own AMRN (from quarterly 13F filings) and who is adding or trimming.
44 institutional holders with $17.3M total value (1,086,176 shares) as of 2026-Q2. Top holders: MORGAN, MILLENNIUM, TWO. Net buying activity: 3 institutions added/increased vs 2 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| MORGAN STANLEY | 223,617 | $3.6M | 20.6% | ADD +65.5% |
| MILLENNIUM MANAGEMENT LLC | 115,808 | $1.8M | 10.7% | TRIM -61.5% |
| TWO SIGMA INVESTMENTS, LP | 100,511 | $1.6M | 9.3% | ADD +85.1% |
| CITADEL ADVISORS LLC | 95,364 | $1.5M | 8.8% | DOUBLED +169.0% |
| BNP PARIBAS FINANCIAL MARKETS | 71,813 | $1.1M | 6.6% | TRIM -27.6% |
| RENAISSANCE TECHNOLOGIES LLC | 48,369 | $771.0K | 4.5% | DOUBLED +151.2% |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 48,000 | $765.1K | 4.4% | — |
| JANE STREET GROUP, LLC | 37,628 | $599.8K | 3.5% | ADD +61.2% |
| SEI INVESTMENTS CO | 29,211 | $465.6K | 2.7% | DOUBLED +134.1% |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 29,001 | $462.3K | 2.7% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| MILLENNIUM MANAGEMENT LLC | TRIM | 300,536 | 115,808 | -61.5% | $1.8M |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 19,256 | 48,369 | +151.2% | $771.0K |
| BlackRock, Inc. | TRIM | 1,164 | 858 | -26.3% | $13.7K |
| JONES FINANCIAL COMPANIES LLLP | DOUBLED | 154 | 493 | +220.1% | $7.8K |
| GROUP ONE TRADING LLC | DOUBLED | 29 | 130 | +348.3% | $2.1K |
| MILLENNIUM MANAGEMENT LLC | ADD | 166,235 | 300,536 | +80.8% | $4.3M |
| Point72 Asset Management, L.P. | DOUBLED | 36,491 | 240,761 | +559.8% | $3.5M |
| BNP PARIBAS FINANCIAL MARKETS | TRIM | 104,345 | 75,503 | -27.6% | $1.1M |
| UBS Group AG | DOUBLED | 4,237 | 13,192 | +211.4% | $190.8K |
| OSAIC HOLDINGS, INC. | TRIM | 24,271 | 9,391 | -61.3% | $135.8K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
12 insiders, 50 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 1, 2026 | Fishman Peter L. | SVP, CFO | EXERCISE | 313 | — | — |
| Aug 1, 2026 | Fishman Peter L. | SVP, CFO | TAX W/H | 155 | $14.26 | $2.2K |
| Aug 1, 2026 | Fishman Peter L. | SVP, CFO | AWARD | 313 | — | — |
| Jul 1, 2026 | Provoost Jonathan | EVP, Chief Legal Officer | AWARD | 3,688 | — | — |
| Jul 1, 2026 | Provoost Jonathan | EVP, Chief Legal Officer | TAX W/H | 1,264 | $15.94 | $20.1K |
| Jul 1, 2026 | Ketchum Steven B | EVP, Chief Scientific Officer | AWARD | 3,688 | — | — |
| Jul 1, 2026 | Ketchum Steven B | EVP, Chief Scientific Officer | TAX W/H | 1,887 | $15.94 | $30.1K |
| Jul 1, 2026 | Provoost Jonathan | EVP, Chief Legal Officer | EXERCISE | 3,688 | — | — |
| Jul 1, 2026 | Ketchum Steven B | EVP, Chief Scientific Officer | EXERCISE | 3,688 | — | — |
| Jul 1, 2026 | Keenan David Paul | EVP, Chief Operating Officer | AWARD | 3,688 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for AMRN.
Shares short
525,845
Settlement Sep 15, 2026
Change vs prior
+2.9%
Semi-monthly cycle
Days to cover
10.1
At avg daily volume
Of shares outstanding
≈2.5%
Estimate — not % of float
All AMRN filing & press-release reports (5)
- PRESS-RELEASE reportAug 28, 2026
- COURT-RULING reportJun 4, 2026
- 8-K reportApr 29, 2026
- PRESS-RELEASE reportMar 16, 2026
- 8-K reportFeb 25, 2026